Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): commentary, Joks et al.
The British journal of psychiatry : the journal of mental science – November 01, 2024
Source: PubMed
Summary
Breakthrough findings show ketamine injections could offer new hope for people with severe depression who haven't responded to traditional treatments. Weekly subcutaneous doses significantly reduced depressive symptoms in patients with major depressive disorder, working faster than conventional medications. While esketamine nasal sprays are already approved, this injection method shows promise as an alternative delivery system.
Abstract
Regarding the article, 'Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial', we commend Loo et al for undertaking the Ketamine for Adult Depression Study (KADS). In the interest of ensuring that accurate and balanced information is presented to healthcare professionals on treatment-resistant depression, we raise several points herein to help clarify and provide additional perspective to the researchers' interpretation of their findings in the Discussion.